PMID: 25764682Mar 15, 2015Paper

Natural human IFNβ and ribavirin combination therapy

Nihon rinsho. Japanese journal of clinical medicine
Satoru Joshita, Eiji Tanaka

Abstract

Chronic hepatitis C virus (HCV) infection results in scarring of the liver and ultimately cirrhosis, liver failure, and hepatocellular carcinoma. One goal of hepatitis C treatment is eradication of the virus, which typically leads an improvement in liver fibrosis. Combination therapies that include interferons (IFNs) and ribavirin increase the rate of a sustained virological response (SVR). Moreover, triple therapy containing direct acting antiviral agents (DAAs) dramatically improves SVR rate, particularly in patients infected with high titer genotype 1b HCV. However, these treatments are accompanied by many serious adverse effects, such as cytopenia and depression, specifically in the elderly. Natural human IFNβ and ribavirin combination therapy is currently available in Japan and is associated with a lower incidence of side effects as compared with IFNα (Peg-IFNα) and ribavirin. Therefore, clinicians should bear IFNβ and ribavirin combination therapy in mind as a well-tolerated and effective option for chronic hepatitis C treatment.

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Expert Opinion on Pharmacotherapy
Nicole Forestier, S Zeuzem
Liver International : Official Journal of the International Association for the Study of the Liver
Ehsaan AkhtarSammy Saab
Expert Opinion on Emerging Drugs
Aybike Birerdinc, Zobair M Younossi
Expert Opinion on Emerging Drugs
Robert FlisiakAnna Parfieniuk-Kowerda
© 2021 Meta ULC. All rights reserved